50 nutraceutical key opinion leaders hosted in Gnosis K2 Global Event

Gnosis had the pleasure to host 50 Turkish nutraceutical key opinion leaders in its manufacturing site of Pisticci, on October 19th.

The event focused also on the “Advanced Nutrition” concept highlighting the optimal features of vitaMK7®, and included the visit to the K2 fermentation production site: it was a great occasion for them to acknowledge the real value of fermentation-derived K2.

Experts held speeches on the main quality advantages of vitaMK7®, the only vitamin K2 as MK7 naturally derived from the fermentation of the Bacillus subtilis natto, whose strain efficacy and safety are widely demonstrated. The reliable supply chain of our K2 manufacturing site, in compliance with the cGMP, ISO and HACCP rules,  guarantees an optimal MK7 with the highest purity (>99%), the real all-trans structure (>99%) and almost no impurities.

Among specialists, we had the valuable support of Prof. Luca Tiano, one of the global leading experts in Vitamin K2 as MK7, who also cooperated with Prof. Gian Paolo Littarru in the release of the new book titled “Vitamin K2 – Facts and perspectives in Biology and Medicine”, presented during the SupplySide West tradeshow held in Las Vegas last month.

We were delighted to host this great K2 Global Event and we would like to thank the whole group for the interest in our innovative concepts!

Folate & Mood: a powerful bond!

Low levels of 5-MTHF, in fact, critically contribute in decreasing the neurotransmitter levels in the cerebrospinal fluid, and in increasing homocysteine levels, some of the main factors that lead to the onset of the mood impairments.

Continuing with the educational plan to increase information on its products & solutions, Gnosis has published a new “News from Science” issue focusing on the link between folate and mood.

Are you interested to learn how Quatrefolic® balances the mood during the several stages of life?

Pregnancy, postpartum, elderly and mood… read our latest “News from Science”!

http://www.quatrefolic.com/news-Folate-Mood-a-powerful-bond.php

Gnosis is one of the best Italian companies able to create economic, technological, human, social and environmental values: all in a sustainable way.

After a rigorous analysis involving 504.000 companies, Gnosis – with its positive economic results and other virtuous behaviours – has been selected among the 70 Italian companies eligible to win the first edition of the Best Performance Awards 2017.

 

The severe evaluation, based on empirical data, surveys, interviews and focus groups and carried out in nearly one year, has allowed to identify the Best Preforming Companies of 2017.

This is another success for Gnosis, let’s go on!

New YouTube video: Emothion® the effective – IN BODY – form of glutathione

The Gnosis-bio YouTube channel never stops: a new video on Emothion®, the effective – IN BODY – form of glutathione, is now available.

Emothion® is a clinically studied and patented new orally stable and crystalline form of S-Acetyl-Glutathione, with enhanced bioavailability and fast action. It is the cutting-edge alternative developed to overcome the poor effectiveness of GSH supplementation, due to its poor absorption and its hydrolytic degradation in the body.

Through the new YouTube video, we want to explain in a new and original language how many advantages come from Emothion® intake: Emothion® has more rapid dissolution rate and, therefore, is orally well absorbed. Once internalized into the cells, it increases GSH level more efficiently than normal GSH.

Take two minutes to watch the new Emothion® YouTube video and enjoy Gnosis-bio channel: what a pleasant and easy way to dive into nutraceutical world!

 

To see the video connect to our website: New-YouTube-video-Emothion.php

Great success for Gnosis at SupplySide West 2017 in Las Vegas: vitaMK7® and Quatrefolic®, two key players

Gnosis played a key role during the SupplySide West trade show, one of the world’s leading event concerning innovative ingredients and solutions for the nutraceutical industry.

Let’s look back at the most significant happenings.

We were proud to present the new book “vitamin K2” recently published by Prof. Gian Paolo Littarru, Professor of Biochemistry at the Polytechnic University of the Marche (Italy) with the cooperation of Dr. Luca Tiano, Associate Professor of Biochemistry.

During the VendorBrief entitled “Vitamin K2 as MK7: Purity, Stability and Trans isomer”, Luca Tiano explained the importance of selecting products containing high-quality fermented derived vitamin K2 as VitaMK7®.

Last release: new Biootic™ Infographic

Probiotic digestive system supplements are on the rise, but not much is known about the different types of probiotics available.

Gnosis has just release a new chart where differences between the two types of probiotics (Yeast and Bacteria based Probiotics) are pointed out, that it might be helpful to know.

To Discover the new Biootic chart, visit http://www.gnosis-bio.com/news-new-biootic-infographic.php and ask for a copy.

INSEA2® GAINS SELF-AFFIRMED GRAS STATUS

RIMOUSKI (QUEBEC), September 18, 2017 – innoVactiv, a Canadian company dedicated to the development of science-based speciality ingredients, is pleased to announce that InSea® recently obtained a self-affirmed Generally Recognized as Safe (GRAS) status. Following a comprehensive evaluation, an independent panel of experts has declared the ingredient safe for various food and beverage applications, including nutritional bars, meal supplement drinks and dietary supplement products.

This certification comes following a positive conclusion of the expert panel’s comprehensive review of the safety aspects of InSea2® intake under the conditions of use as a food ingredient. “This self-affirmed GRAS status is yet another indication of our strong commitment to continuously improve our ingredient’s scientific foundations, both on the efficacy and safety aspects”, said Jocelyn Bérubé, Executive Vice President – Scientific & Regulatory affairs for innoVactiv.

“We are very happy to reach this significant milestone”, said Patrice Dionne, Chief Executive Officer for innoVactiv. “InSea2® is a highly-effective glucose optimizer which now occupies an enviable place on the market. The GRAS status will allow us to diversify our positioning by attracting a new fringe of consumers more interested by functional food products than dietary supplements.”

The announcement is made a few days prior to the Supply Side West Show in Las Vegas, on September 27 and 28, 2017 where innoVactiv will be presenting at booth F-136. It will be possible to have more information about these exciting developments at the Las Vegas Show. InSea®, innoVactiv’s leading nutraceutical ingredient, has demonstrated its ability in several clinical studies to promote better blood sugar control and maintain cognitive functions. Its positive effect on glycemia can also be applied to weight loss applications.

Quatrefolic® and male infertility: meta-analyses report new highlights about the potential risk of MTHFR polymorphism in folate metabolism

Methyltetrahydrofolate reductase (MTHFR) is one of the most important enzyme in human physiology, and its deficiencies in production or function have been associated with increased risk in pregnancy and other human diseases. MTHFR polymorphism is one of the main area of current research.

In the recent months, new several publications have investigated the potential effects of the MTHFR enzyme polymorphism on folate metabolism and its association with increased risk of congenital malformations, degenerative diseases and decreasing health and wellbeing in old age.

Population with MTHFR gene variation partially metabolize folic acid and food folate to the active form 5-MTHF and is not able to maintain an adequate folate status during all life stages.

Notable, two different meta-analysis correlated the polymorphism with risk of male infertility:

  • Hong at al. took in consideration a total of 15 studies with 3853 patients with infertility and 3613 healthy controls. Results showed that T variant of MTHFR C677T gene polymorphism was significantly associated with an increased risk of male infertility
  • Zhang et al. included a total of 20 studies with 4293 cases and 4507 controls found that the A variant of MTHFR A1298C may be a potential risk factor for male infertility, especially in the Asian population.

Quatrefolic® completely bypasses the “damaged” MTHFR conversion step and delivers a “finished” folate that can be immediately use by the body without any kind of metabolization, reducing the risk of degenerative diseases and increasing health and wellbeing.

 

See comment in PubMed Commons below

References:

Hong at al. “Associations of C677T polymorphism in methylenetetrahydrofolate reductase (MTHFR) gene with male infertility risk: A meta-analysis” Eur J Obstet Gynecol Reprod Biol. 2017

 

Zhang et al “Association between MTHFR A1298C polymorphism and male infertility: A meta-analysis.” J Huazhong Univ Sci Technolog Med Sci. 2017

New Study Links Mental and Physical Performance

A recent study showed supplementation with Neumentix™ Phenolic Complex K110-42 improved cognitive and physical performance after 30 days. Notably, this improvement was sustained through the length of the 90-day study.

The new study used a novel device called the Makoto Arena, a physical assessment tool that links mental and physical performance. Neumentix supplementation showed improvements in choice reaction performance, agility and cross-body movements. Stop by the Kemin Science Discovery Center at Supply Side West to try out the Makoto Arena!

Neumentix is a clinically-studied nootropic ingredient that supports sustained attention and concentration. New research continues to unveil new benefits of this sustainably-grown spearmint extract. Click below to download the whitepaper on the new clinical study.

Download White Paper

Longvida® new research

A recent clinical publication in a peer-reviewed journal, JCI Insight, o ers a practical, noninvasive approach to detect and monitor discrete retinal amyloid deposits in patients using solid-lipid curcumin and a modi ed scanning laser ophthalmoscope. The researchers conclude that the concept may lead to a practical and feasible approach for large-scale AD diagnosis and monitoring.2

The researchers present an extensive amount of quantitative and histological reports including comparative curcumin data (water soluble, 95% curcuminoids, Longvida®) pharmacokinetic information, dose and regimen calibration, as well as human clinical data.2

In one retinal imaging proof-of-concept report (n = 16), Longvida® Optimized Curcumin was administered orally in healthy and AD subjects. Fundus images showed increased uorescent intensity in retinal deposits at days 1 and 10 compared to baseline. The researchers found that the Longvida oral curcumin formulation consistently co-labeled Aβ plaques.2

Further, pharmacokinetic analysis in six subjects on a 10-day regimen of Longvida® Optimized Curcumin indicated a signi cant increase in curcumin levels in both free plasma and red blood cells (see Figure E).2

Tissue curcumin levels in red blood cells (RBCs) and free curcumin in plasma
peaked at day 10 (P < 0.0001). The results of free curcumin analysis in plasma and
RBCs at day 30 (washout) con rms previous reports of extended transfer of
Longvida’s curcumin into the bloodstream and other target tissues1. “The high bioavailability of optimized curcumin was established by increased tissue absorption of free rather than glucuronidated or other curcumin metabolites from the gastrointestinal system to the blood stream.”2

Supplemental data compared three commercially available curcumins for their absorption into the brain and red blood cells, resulting in the highest brain concentrations of free curcumin obtained with Longvida® Optimized Curcumin (see Figure 4B).2

“We are extremely honored to have Longvida® included in this ground breaking trial by such an accomplished group of research experts,” says Kristen Marshall, Marketing Coordinator at Verdure Sciences. “Not only is this an incredible trial, but the publication is incredibly extensive and includes such an immense wealth of information and data that is unlike any other publication to include Longvida. Further, the potential implications of this proof-of-concept trial are profound and very exciting to be a part of.”

References:
1 Gota VS et al. Safety and pharmacokinetics of a solid lipid curcumin particle formulation. J Agric Food Chem. 2010. 58(4): 2095-99. 2 Koronyo Y et al. Retinal amyloid pathology and proof-of-concept imaging trial. JCI Insight. 2017. 2(16).